{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:40Z","timestamp":1791335620809,"version":"4.3.1"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Malignant mesothelioma (MM) is a rare and aggressive neoplasm, usually associated with a poor prognosis (5 years survival rate &amp;lt;10%). For unresectable disease, platinum and pemetrexed chemotherapy has been the only standard of care in first line for more than two decades, while no standard treatments have been approved in subsequent lines. Recently, immunotherapy has revolutionized the therapeutic landscape of MM. In fact, the combination of ipilimumab plus nivolumab has been approved in first line setting. Moreover, immune checkpoint inhibitors (ICIs) showed promising results also in second-third line setting after platinum-based chemotherapy. Unfortunately, approximately 20% of patients are primary refractory to ICIs and there is an urgent need for reliable biomarkers to improve patient\u2019s selection. Several biological and molecular features have been studied for this goal. In particular, histological subtype (recognized as prognostic factor for MM and predictive factor for chemotherapy response), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden (widely hypothesized as predictive biomarkers for ICIs in several solid tumors) have been evaluated, but with unconclusive results. On the other hand, the deep analysis of tumor infiltrating microenvironment and the improvement in genomic profiling techniques has led to a better knowledge of several mechanisms underlying the MM biology and a greater or poorer immune activation. Consequentially, several potential biomarkers predictive of response to immunotherapy in patients with MM have been identified, also if all these elements need to be further investigated and prospectively validated.<\/jats:p><jats:p>In this paper, the main evidences about clinical efficacy of ICIs in MM and the literature data about the most promising predictive biomarkers to immunotherapy are reviewed.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1121557","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T06:04:40Z","timestamp":1674799480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress"],"prefix":"10.3389","volume":"14","author":[{"given":"Matteo","family":"Perrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"De Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Cordua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Borea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aliprandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2072211","article-title":"Advances in drug treatments for mesothelioma","volume":"23","author":"Zucali","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164194","article-title":"Epidemiology and clinical aspects of malignant pleural mesothelioma","volume":"13","author":"Brims","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051034","article-title":"The evolving landscape of the molecular epidemiology of malignant pleural mesothelioma","volume":"10","author":"Lettieri","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010182","article-title":"Salvage therapy for relapsed malignant pleural mesothelioma: A systematic review and network meta-analysis","volume":"14","author":"Tsai","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma(CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: Results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","article-title":"PrE0505: phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) \u2014 a PrECOG LLC study","volume":"38","author":"Forde","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: The European organization for research and treatment of cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia group b","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bill\u00e9","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"21357","DOI":"10.1038\/s41598-021-00831-4","article-title":"Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort","volume":"11","author":"Cedres","year":"2021","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.03.001","article-title":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"96","author":"Cedr\u00e9s","year":"2016","journal-title":"Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by dako PD-L1 22C3 pharmDx and dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2021","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","article-title":"Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma","volume":"21","author":"Gray","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"De Gooijer","year":"2020","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.11.006","article-title":"Immune checkpoint inhibitor therapy for malignant pleural mesothelioma","volume":"162","author":"Nowak","year":"2021","journal-title":"Lung Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5950","article-title":"Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice","volume":"6","author":"Campesato","year":"2015","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.11.009","article-title":"CheckMate 743: A glimmer of hope for malignant pleural mesothelioma","volume":"22","author":"Uprety","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01567","article-title":"New era for malignant pleural mesothelioma: Updates on therapeutic options","volume":"40","author":"Tsao","year":"2022","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"19138","DOI":"10.1038\/s41598-021-98414-w","article-title":"Integrated genomics point to immune vulnerabilities in pleural mesothelioma","volume":"11","author":"Nastase","year":"2021","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumor immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discovery"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumor microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor immune microenvironment and genetic alterations in mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/s41467-021-22142-y","article-title":"The therapeutic implications of the genomic analysis of malignant pleural mesothelioma","volume":"12","author":"Zauderer","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0983","article-title":"TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma","volume":"9","author":"Hodi","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2790","article-title":"Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 ipilimumab in gastric Cancer\/Gastroesophageal junction cancer","volume":"27","author":"Lei","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumabtreated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.870352","article-title":"Prognostic role of tumor immune microenvironment in pleural epithelioid mesothelioma","volume":"12","author":"Ollila","year":"2022","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumor-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumor-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30284","article-title":"Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: A multicentre, retrospective analysis","volume":"6","author":"Duruisseaux","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2020","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03204-6","article-title":"Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis","volume":"71","author":"Yoshida","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br J Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105786","article-title":"Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: Results from the MATCH study","volume":"23","author":"Mannarino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2590","article-title":"Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers","volume":"20","author":"Di Caro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","article-title":"B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma","volume":"10","author":"Griss","year":"2019","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer","volume":"5","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916839","article-title":"Novel insights into mesothelioma therapy: Emerging avenues and future prospects","volume":"12","author":"Kuryk","year":"2022","journal-title":"Front Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133205","article-title":"The immune microenvironment of malignant pleural mesothelioma: A literature review","volume":"13","author":"D\u00e9sage","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32363","article-title":"NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy","volume":"145","author":"Sottile","year":"2019","journal-title":"Int J Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-010-0448-x","article-title":"Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma","volume":"34","author":"Wang","year":"2010","journal-title":"World J Surg"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"Phase II trial of pembrolizumab (NCT02399371) in previously treated malignant mesothelioma: Final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100135","article-title":"Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study","volume":"2","author":"Fujimoto","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103374","article-title":"TMB or not TMB as a biomarker: That is the question","volume":"163","author":"Addeo","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030673","article-title":"Recent advances of immune checkpoint inhibition and potential for (Combined) TIGIT blockade as a new strategy for malignant pleural mesothelioma","volume":"10","author":"Rovers","year":"2022","journal-title":"Biomedicines"},{"key":"B94","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/annonc\/mdz266","article-title":"Second or third line nivolumab versus nivolumab plus ipilimumab in malignant pleural mesothelioma patients: Long-term results of the IFCT-1501 MAPS2 randomized phase 2 trial with a focus on hyperprogression","volume":"30","author":"Zalcman","year":"2019","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3757","article-title":"Tumor-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients","volume":"24","author":"Khanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-Domain ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod Pathol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0328-3","article-title":"Expression of V-set immunoregulatory receptor in malignant mesothelioma","volume":"33","author":"Chung","year":"2020","journal-title":"Mod Pathol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188386","article-title":"Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types","volume":"1874","author":"Van Den Ende","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T06:04:43Z","timestamp":1674799483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2023.1121557"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1121557","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"article-number":"1121557"}}